当前位置: X-MOL 学术Lancet Respir. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Strict adherence rules to obtain monoclonal therapy might cost lives
The Lancet Respiratory Medicine ( IF 76.2 ) Pub Date : 2017-06-27 , DOI: 10.1016/s2213-2600(17)30238-2
Ruth H Green , Dominick Shaw

Asthma drugs targeting so-called T2 pathophysiology are now in use.1 The first drug, called mepolizumab, an anti-interleukin-5 monoclonal antibody, has been approved by the National Institute for Health and Care Excellence (NICE).2 Other anti-interleukin-5 antibodies are being assessed, and monoclonal antibodies targeting interleukin 4, interleukin 13, and interleukin 33 are likely to follow. These drugs widen the treatment options available for patients with severe asthma who remain uncontrolled despite standard high-dose inhaled or oral corticosteroids, or omalizumab (anti-IgE) therapy.


中文翻译:

严格的依从性规则以获得单克隆治疗可能会导致生命损失



现在正在使用针对所谓的T2病理生理学的哮喘药物。1第一种药物称为mepolizumab,一种抗白介素5单克隆抗体,已获得美国国立卫生与医疗保健研究院(NICE)的批准。2其他抗白介素5抗体正在评估中,针对白介素4,白介素13和白介素33的单克隆抗体可能会问世。这些药物扩大了严重哮喘患者的治疗选择,这些患者尽管采用标准的大剂量吸入或口服皮质类固醇或奥马珠单抗(抗IgE)疗法仍无法控制。
更新日期:2017-08-10
down
wechat
bug